Log In
Print this Print this

Vpriv, velaglucerase alfa (GA-GCB)

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionGlucocerebrosidase enzyme replacement therapy
Molecular Target Not applicable
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationGaucher's disease
Indication DetailsTreat Gaucher's disease; Treat Type I Gaucher's disease
Regulatory Designation U.S. - Priority Review (Treat Type I Gaucher's disease);
EU - Orphan Drug (Treat Type I Gaucher's disease);
Japan - Standard Review (Treat Gaucher's disease);
Switzerland - Orphan Drug (Treat Type I Gaucher's disease)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today